United States · Telehealth platform · Brand-name and compounded
Remedy Meds review
Publishes batch-testing detail almost nobody else does — and received an FDA warning letter in September 2025 over its marketing claims.
Overview
Remedy Meds offers compounded semaglutide and tirzepatide plus a microdose plan, alongside brand-name Ozempic and Zepbound, stating it sources “compounded GLP-1s exclusively from U.S. pharmacies.” Its quality disclosure is the most specific in this research: “every batch passes four independent tests before it ships” — potency, sterility, pH and endotoxicity. Nobody else names the assays.
Service terms are good too: dosing personalised within 24 hours of signup, monthly clinician check-ins, unlimited video calls and messaging, shipping within 48 hours direct from licensed US compounding pharmacies every 28 days, HSA/FSA accepted, and pause, adjust or cancel anytime. No pricing is published.
The material fact a buyer needs is not on the company’s own site. The FDA issued Remedy Meds a warning letter dated 9 September 2025 (MARCS-CMS 716830) stating that “your claims concerning compounded semaglutide and tirzepatide products are false or misleading under sections 502(a) and 502(bb)” of the Federal Food, Drug, and Cosmetic Act. Batch testing addresses what is in the vial; a warning letter about marketing claims addresses what you were told about it.
Medications and supply
Both. Compounded products are sourced exclusively from US pharmacies and batch-tested for potency, sterility, pH and endotoxicity.
- Compounded semaglutide
- Compounded tirzepatide
- Compounded GLP-1 microdose plan
- Ozempic (semaglutide)
- Zepbound (tirzepatide)
How the service works
- Consultation
- Personalised dosing within 24 hours of signup, by licensed clinicians experienced in GLP-1 care.
- Eligibility
- Determined by the reviewing clinician.
- Provider involvement
- Monthly clinician check-ins with adjustments as needed, plus unlimited video calls and messaging.
- Lab requirements
- Not stated in the sources we checked.
- Pharmacy fulfilment
- Licensed US compounding pharmacies, shipping every 28 days. Batch testing covers potency, sterility, pH and endotoxicity.
- Shipping
- Ships within 48 hours, free and discreet, every 28 days.
- Support services
- Unlimited video calls and messaging with your clinician.
What it costs
| Item | Published price | Notes |
|---|---|---|
| All plans | not published | month-to-month, cancel anytime |
- Membership fee
- Not stated in the sources we checked.
- Medication fee
- Not published.
- Insurance
- Not stated in the sources we checked.
- HSA / FSA
- Accepted.
- Cancellation
- Remedy Meds states you can pause, adjust or cancel anytime.
- Refunds
- A weight-loss warranty is referenced in its terms of service but the terms are not stated on the page.
Pros
- Names the batch tests performed — potency, sterility, pH and endotoxicity — which nobody else does
- Monthly clinician check-ins and unlimited video calls
- Ships within 48 hours, free, on a 28-day cycle
- HSA/FSA accepted, pause or cancel anytime
Cons
- Received an FDA warning letter in September 2025 over false or misleading claims about its compounded semaglutide and tirzepatide products
- No pricing published at all
- The warranty terms are off-page
- Nothing published on labs
Who it may suit
Hard to recommend without addressing the warning letter. If you are considering it, read the FDA letter first — it is linked in our sources.
Limitations
- Compounded products are not FDA-approved
- An open FDA enforcement action about marketing claims is a materially different risk from the ordinary compounding caveat
Questions
What did the FDA warning letter say?
The letter, dated 9 September 2025 (MARCS-CMS 716830), states that Remedy Meds’ claims concerning its compounded semaglutide and tirzepatide products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act. Read it directly — we have linked it.
Does the batch testing make it safe?
Batch testing for potency, sterility, pH and endotoxicity is more than almost anyone else publishes, and it addresses what is in the vial. It does not address the marketing claims the FDA letter concerns, which are a separate issue.
Sources
Everything on this page traces to one of the links below, retrieved on the date shown. Prices and programme terms in this market change without notice — confirm against the provider before you buy.